BioLexa Platform
Atopic Dermatitis (Eczema)
Phase 2Active
Key Facts
About Hoth Therapeutics
Hoth Therapeutics is a US-based, publicly traded biopharmaceutical company (NASDAQ: HOTH) dedicated to developing innovative, targeted therapeutics for conditions with high unmet need, particularly in dermatology and chronic wound care. Its primary asset is the proprietary BioLexa Platform, a topical treatment in development for atopic dermatitis (eczema). The company's strategy involves leveraging this platform technology to expand its pipeline across oncology, neurology, and inflammatory dermatology while operating as a pre-revenue, clinical-stage entity subject to the volatility of the micro-cap biotech sector.
View full company profileTherapeutic Areas
Other Atopic Dermatitis (Eczema) Drugs
| Drug | Company | Phase |
|---|---|---|
| CCR4 Antagonist Program | RAPT Therapeutics | Phase 2 (assumed) |